Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PD-L1 Antibody”

361 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 361 results

Testing effectiveness (Phase 2)Study completedNCT02574598
What this trial is testing

MK-3475 in Combination With Docetaxel vs Docetaxel Alone in Non-Small Cell Lung Cancer Patients

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Instituto Nacional de Cancerologia de Mexico 78
Testing effectiveness (Phase 2)Study completedNCT03707587
What this trial is testing

M7824 in People With Recurrent Respiratory Papillomatosis

Who this might be right for
Recurrent Respiratory PapillomatosisRespiratory PapillomatosisLaryngeal Papilloma, Recurrent+1 more
National Cancer Institute (NCI) 9
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07471165
What this trial is testing

A Prospective, Single-Arm, Phase II Study: PD-L1 Monoclonal Antibody + Chemoradiotherapy as Bridge Therapy to Liver Transplantation for Locally Advanced Perihilar Cholangiocarcinoma (ACHIEVE-LT)

Who this might be right for
Locally Advanced Perihilar Cholangiocarcinoma
The First Affiliated Hospital with Nanjing Medical University 25
Large-scale testing (Phase 3)Active Not RecruitingNCT05943795
What this trial is testing

A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma

Who this might be right for
Non-small Cell Lung AdenocarcinomaSquamous Cell Carcinoma of Lung
Sichuan Baili Pharmaceutical Co., Ltd. 589
Testing effectiveness (Phase 2)Looking for participantsNCT06953089
What this trial is testing

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

Who this might be right for
Solid Tumors
DualityBio Inc. 492
Testing effectiveness (Phase 2)Looking for participantsNCT06978114
What this trial is testing

BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer

Who this might be right for
Advanced Biliary Tract Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 46
Testing effectiveness (Phase 2)Looking for participantsNCT03907475
What this trial is testing

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

Who this might be right for
Locally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm
National Cancer Institute (NCI) 115
Early research (Phase 1)Ended earlyNCT03292172
What this trial is testing

Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer

Who this might be right for
Advanced Ovarian CancerTriple Negative Breast Cancer
Hoffmann-La Roche 36
Very early researchLooking for participantsNCT07274813
What this trial is testing

A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors

Who this might be right for
Advanced/Metastatic Solid TumorsNSCLC
Shanghai Henlius Biotech 254
Testing effectiveness (Phase 2)Active Not RecruitingNCT05604560
What this trial is testing

A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer

Who this might be right for
Pancreatic Cancer
Lei Zheng 25
Large-scale testing (Phase 3)Looking for participantsNCT06103864
What this trial is testing

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

Who this might be right for
Breast Cancer
AstraZeneca 625
Testing effectiveness (Phase 2)Study completedNCT04115111
What this trial is testing

Diadem to Investigate the Activity and Safety of Durvalumab

Who this might be right for
Pleura Mesothelioma
Mario Negri Institute for Pharmacological Research 57
Testing effectiveness (Phase 2)Study completedNCT02628132
What this trial is testing

Study of Safety and Efficacy of Durvalumab in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer Patients

Who this might be right for
Breast Cancer
King Faisal Specialist Hospital & Research Center 22
Testing effectiveness (Phase 2)Looking for participantsNCT04777084
What this trial is testing

The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC.

Who this might be right for
Non-Small Cell Lung Cancer
Hunan Province Tumor Hospital 120
Testing effectiveness (Phase 2)Ended earlyNCT04260802
What this trial is testing

Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

Who this might be right for
CancerNeoplasmsMetastatic Cancer+16 more
Ocellaris Pharma, Inc. 73
Testing effectiveness (Phase 2)Active Not RecruitingNCT05215067
What this trial is testing

A Phase II Trial of AK104 in Advanced Non-Small Cell Lung Cancer

Who this might be right for
Advanced Non-small Cell Lung Cancer
Akeso 44
Large-scale testing (Phase 3)Active Not RecruitingNCT04746924
What this trial is testing

Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

Who this might be right for
Non-small Cell Lung CancerNSCLC
BeiGene 662
Not applicableLooking for participantsNCT06693440
What this trial is testing

The Immune Assessment of PD-1 Antibody Therapy in Tumor

Who this might be right for
Efficacy, TeamAdverse Event
Quanli Gao 3,000
Not applicableLooking for participantsNCT05717738
What this trial is testing

Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma Non-resectable
Tongji Hospital 300
Testing effectiveness (Phase 2)Study completedNCT02489448
What this trial is testing

Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer

Who this might be right for
Breast Neoplasms
Yale University 68
Load More Results